Stock PVCT PROVECTUS BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Provectus Biopharmaceuticals, Inc. OTC Bulletin Board

Equities

PVCT

US74373P1084

End-of-day quote OTC Bulletin Board
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Provectus Biopharmaceuticals, Inc. -.--% -.--%
Apr. 16 Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President CI
Apr. 16 Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
AQ
Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President
CI
Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer
CI
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
AQ
Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
CI
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
AQ
Provectus Biopharmaceuticals, Inc. Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
CI
Provectus Biopharmaceuticals, Inc. Announces Management Changes
CI
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
AQ
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
AQ
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PHARMACEUTICAL-GRADE ROSE BENGAL SODIUM ABSTRACT FOR POSTER PRESENTATION AT 2024 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING
AQ
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
AQ
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
AQ
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
AQ
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
AQ
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma
CI
Provectus: Q3 Earnings Snapshot
AQ
Provectus Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PVCT Stock
  4. PVCT Stock
  5. News Provectus Biopharmaceuticals, Inc.